Alloy vs Mevo Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alloy
Best for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directoryStarting at $80/mo
Mevo Health
Best for Patients wanting a physician-network-led compounded GLP-1 plan with both injection and oral-tablet options for both semaglutide and tirzepatide, on monthly/quarterly/six-month flexibility. Best for buyers who do not require a published per-state availability list or named pharmacy partner upfront.Starting at $199/mo
Side-by-Side Comparison
| Feature | Alloy | Mevo Health |
|---|---|---|
| Overall Score | ✓7.4/10 | 5.8/10 |
| Starting Price | ✓$80/mo | $199/mo |
| Editorial Rating | ✓3.7 ★ /5 | 2.9 ★ /5 |
| Features | 8 features | ✓10 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alloy
Pros
- ✓Broadest GLP-1 formulary in our catalog: brand Wegovy + brand Zepbound + oral Wegovy + compounded semaglutide + compounded tirzepatide + compounded liraglutide
- ✓All consulting doctors are certified by The Menopause Society — only ~1,000 such certified practitioners exist among ~20,000 OB-GYNs in the US
- ✓Brand-name Wegovy starting at $199/mo and compounded liraglutide starting at $80/mo cover both ends of the price/access spectrum
- ✓STARTGLP1 promo code knocks $50 off the first month per the public site
Cons
- ✗Not available in Louisiana or Mississippi (verified) — readers in those two states should be routed elsewhere
- ✗Initial consultation is $49 and is separate from medication cost — readers should know there's a non-refundable upfront fee
- ✗Menopause-specialty framing — best fit for women in menopause/perimenopause, not the right product for men or younger women whose primary need is weight loss
Mevo Health
Pros
- ✓**LegitScript verification badge** present on multiple site pages
- ✓**Verbatim FDA compounded-medication disclaimer** present (transparency win)
- ✓**Four named board-certified physicians** disclosed (Wasef, Suppa, Sakla, Chikando)
- ✓**Both molecules in both routes** offered (sema + tirz in injection AND oral tablet) — rare in DTC space
- ✓Public pricing surfaced (entry-price ‘as low as’)
- ✓Plan flexibility (monthly / quarterly / six-month)
- ✓Operating entity disclosed (Mevo Health LLC, Delaware)
Cons
- ✗**States served not enumerated** on any public page (homepage, contact, terms, privacy)
- ✗**Pharmacy partners not named** — only described as ‘503A U.S. compounding pharmacies’ with two unlabeled logos
- ✗**No Medical Director named by title** — Dr. David Wasef is ‘head of the Mevo Provider Network’ but no formal Medical Director role disclosed
- ✗**Pricing is ‘as low as’ floor only** — per-dose itemization not surfaced publicly
- ✗No SOC 2 certification claimed
- ✗Footer typo: ‘HIPPA Policy’ link text
- ✗Clinical-services-PC overlap with Wasef Health PC pattern (Vytora, Ondra, Cora, Refills, sermorelin.com) — not a duplicate brand but worth disclosing
Our Verdict
Alloy edges out Mevo Health with a higher overall score of 7.4/10 and is particularly strong for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory. Mevo Health remains a solid alternative, especially if you're looking for Patients wanting a physician-network-led compounded GLP-1 plan with both injection and oral-tablet options for both semaglutide and tirzepatide, on monthly/quarterly/six-month flexibility. Best for buyers who do not require a published per-state availability list or named pharmacy partner upfront..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.